Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation

Annals of Neurology

Volumn 77, Issue 5, 2015, Pages 784-803

  Göb, Eva ^a   Reymann, Stephan ^a   Langhauser, Friederike ^a   Schuhmann, Michael K ^a   Kraft, Peter ^a   Thielmann, Ina ^a   Göbel, Kerstin ^b   Brede, Marc ^c   Homola, György ^a   Solymosi, Lászlõ ^a   Stoll, Guido ^a   Geis, Christian ^d   Meuth, Sven G ^b   Nieswandt, Bernhard ^a   Kleinschnitz, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BRADYKININ; ESTRADIOL; HIGH MOLECULAR WEIGHT KININOGEN; MESSENGER RNA; OCCLUDIN; PLASMA KALLIKREIN; PLASMA KALLIKREIN ANTIBODY; PREKALLIKREIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOTTING; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; COORDINATION; ESTRADIOL BLOOD LEVEL; ESTRUS CYCLE; FEMALE; GENOTYPE; HEART RATE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN INFARCTION; C57BL MOUSE; GENETICS; KNOCKOUT MOUSE; METABOLISM; STROKE; THROMBOSIS;

ANIMALS; BRAIN INFARCTION; FEMALE; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMA KALLIKREIN; STROKE; THROMBOSIS;

EID: 84928205309     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24380     Document Type: Article

References (53)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245-254.
2. Stoll G, Kleinschnitz C, Nieswandt B,. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 2008; 112: 3555-3562.
3. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-518.
4. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121: 1510-1517.
5. Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17.
6. Pham M, Stoll G, Nieswandt B, et al. Blood coagulation factor XII-a neglected player in stroke pathophysiology. J Mol Med 2012; 90: 119-126.
7. Albert-Weissenberger C, Sirén AL, Kleinschnitz C,. Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system. Prog Neurobiol 2013; 102: 65-82.
8. Magnus T, Wiendl H, Kleinschnitz C,. Immune mechanisms of stroke. Curr Opin Neurol 2012; 25: 334-340.
9. Nieswandt B, Kleinschnitz C, Stoll G,. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 2011; 589: 4115-4123.
10. Björkqvist J, Jämsä A, Renné T,. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
11. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-5311.
12. Heydenreich N, Nolte MW, Göb E, et al. C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke 2012; 43: 2457-2467.
13. Langhauser F, Göb E, Kraft P, et al. Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012; 120: 4082-4092.
14. Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
15. Liu J, Gao BB, Clermont AC, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 2011; 17: 206-210.
16. Renné T, Gruber A,. Plasma kallikrein: novel functions for an old protease: Thromb Haemost 2012; 107: 1012-1013.
17. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010; 8 (9).
18. Kraft P, Göb E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke 2013; 44: 3202-3210.
19. Dirnagl U, Fisher M,. International, multicenter randomized preclinical trials in translational stroke research: it's time to act. J Cereb Blood Flow Metab 2012; 32: 933-935.
20. Schulze-Topphoff U, Prat A, Prozorovski T, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009; 15: 788-793.
21. Whitten WK,. Modification of the oestrous cycle of the mouse by external stimuli associated with the male. J Endocrinol 1956; 13: 399-404.
22. Caligioni CS,. Assessing reproductive status/stages in mice. Curr Protoc Neurosci 2009; Appendix 4: Appendix 4I.
23. Mukai K, Nakajima Y, Urai T, et al. 17β-Estradiol administration promotes delayed cutaneous wound healing in 40-week ovariectomised female mice. Int Wound J (in press). Doi: 10.1111/iwj.12336.
24. Haisenleder DJ, Schoenfelder AH, Marcinko ES, et al. Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays. Endocrinology 2011; 152: 4443-4447.
25. Stegner D, Thielmann I, Kraft P, et al. Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke-brief report. Arterioscler Thromb Vasc Biol 2013; 33: 2212-2217.
26. Kleinschnitz C, Kraft P, Dreykluft A, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2013; 121: 679-691.
27. Brede M, Braeuninger S, Langhauser F, et al. α(2)-Adrenoceptors do not mediate neuroprotection in acute ischemic stroke in mice. J Cereb Blood Flow Metab 2011; 31: 27-34.
28. Schuhmann MK, Kraft P, Stoll G, et al. CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke. J Cereb Blood Flow Metab 2015; 35: 6-10.
29. Wagner S, Kalb P, Lukosava M, et al. Activation of the tissue kallikrein-kinin system in stroke. J Neurol Sci 2002; 202: 75-76.
30. Schmaier AH,. Physiologic activities of the contact activation system. Thromb Res 2014; 133: 41-44.
31. Roy-O'Reilly M, McCullough LD,. Sex differences in stroke: the contribution of coagulation. Exp Neurol 2014; 259: 16-27.
32. Hurn PD, Macrae IM,. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab 2000; 20: 631-652.
33. Gibson CL, Gray LJ, Murphy SP, Bath PMW,. Estrogens and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab 2006; 26: 1103-1113.
34. Bird JE, Smith PL, Wang X, et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-1150.
35. Ten VS, Yao J, Ratner V, et al. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J Neurosci 2010; 30: 2077-2087.
36. Siegerink B, Govers-Riemslag JW, Rosendaal FR, et al. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 2010; 122: 1854-1861.
37. Pfeilschifter W, Spitzer D, Czech-Zechmeister B, et al. Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice. Stroke 2011; 42: 1116-1121.
38. Kraft P, De Meyer SF, Kleinschnitz C,. Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. J Cereb Blood Flow Metab 2012; 32: 1831-1840.
39. Qian Y, Pan J, Zhou X, et al. Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis. Prog Mol Biol Transl Sci 2010; 93: 395-421.
40. Abdallah RT, Keum JS, El-Shewy HM, et al. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 2010; 285: 35206-35215.
41. Portelli MA, Siedlinski M, Stewart CE, et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J 2014; 28: 923-934.
42. Jia Q, Zhao X, Wang C, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke 2011; 42: 2758-2762.
43. Álvarez-Sabín J, Maisterra O, Santamarina E, Kase CS,. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol 2013; 12: 689-705.
44. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59: 669-674.
45. Neumann-Haefelin T, du Mesnil de Rochemont R, Fiebach JB, et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke 2004; 35: 109-114.
46. Zanette EM, Roberti C, Mancini G, et al. Spontaneous middle cerebral artery reperfusion in ischemic stroke. A follow-up study with transcranial Doppler. Stroke 1995; 26: 430-433.
47. Stadnicki A, Sartor RB, Janardham R, et al. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J 1998; 12: 325-333.
48. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13: 181-188.
49. Arumugam TV, Salter JW, Chidlow JH, et al. Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol 2004; 287: 2555-2560.
50. Zimmerli W, Huber I, Bouma BN, Lämmle B,. Purified human plasma kallikrein does not stimulate but primes neutrophils for superoxide production. Thromb Haemost 1989; 62: 1121-1125.
51. Bernstein JA, Qazi M,. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 2010; 6: 29-39.
52. Storini C, Bergamaschini L, Gesuete R, et al. Selective inhibition of plasma kallikrein protects brain from reperfusion injury. J Pharmacol Exp Ther 2006; 318: 849-854.
53. Dirnagl U, Klehmet J, Braun JS, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 2007; 38: 770-773.